Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers testing virus-gene therapy combination against melanoma

06.07.2009
Researchers at the Moores UCSD Cancer Center are injecting a modified herpes virus into melanoma tumors, hoping to kill the cancer cells while also bolstering the body's immune defenses against the disease.

Gregory Daniels, MD, PhD, assistant clinical professor of medicine at the UC San Diego School of Medicine and his co-workers are comparing the modified virus treatment, called OncoVEX GM-CSF, to general immune system stimulation with the immune-boosting protein GM-CSF in an international phase III trial for patients with advanced melanoma. The Moores UCSD Cancer Center is the only site in San Diego for the clinical trial.

Melanoma, the most dangerous kind of skin cancer, takes about 60,000 lives a year in this country. "Melanoma has always been curable, but only in a small fraction of patients," Daniels said. "Local tumor killing with immune activation may provide an additional tool to increase this number to a larger population of cancer patients."

According to Daniels, the injected virus appears to preferentially infect cancer cells, leading to tumor death. The expression of the GM-CSF protein may also direct an immune attack against both infected and non-infected tumors. The virus has in essence been genetically reprogrammed to target the cancer cells, while healthy cells remain relatively untouched. The research team is testing the two-pronged attack of direct tumor cell killing and immune activation. Their aim is to see if it will help those patients whose cancer has spread to other areas of the body to live longer without disease than has been possible with standard therapies.

While the field of cancer immunotherapy – employing the body's own immune system to fight cancer – has had mixed results to date, Daniels remains hopeful. Earlier stage testing showed that about 26 percent of patients receiving the OncoVEX GM-CSF therapy had either a partial or complete response, meaning their cancer either stopped growing or regressed.

Daniels said that while the therapy has been shown in earlier testing to destroy the injected tumors to some degree, it also causes a general change in the immune system, occasionally shrinking uninjected tumors. "It's a more active type of immunotherapy, causing a cascade of immune system activity in the body," he said.

The team hopes to enroll 30 patients with advanced melanoma. The cancer in these individuals cannot be removed surgically, and the patients must have had one failed prior therapy. The goal of the trial is not necessarily to cure the patients of their cancer, but to enable them to live disease-free for at least six months and longer. In all, 360 patients worldwide will ultimately participate in the trial. Twice as many patients will get the virus as will get the GM-CSF alone. As this is not a blinded study, those running the trial will know who is getting which therapy, but the treatments are randomly assigned to participants.

The virus infection-immune system-boosting approach could potentially be used for other types of cancers, Daniels said, such as colon, breast, prostate, bladder and lung.

OncoVEX GM-CSF is made by BioVex, a Woburn, MA-based biotechnology company.

For more information about this trial, please contact Trang Tran, clinical trials coordinator, at 858-822-4171 or melanoma@ucsd.edu.

The Moores UCSD Cancer Center is one of the nation's 41 National Cancer Institute-designated Comprehensive Cancer Centers, combining research, clinical care and community outreach to advance the prevention, treatment and cure of cancer.

Steve Benowitz | EurekAlert!
Further information:
http://www.ucsd.edu
http://health.ucsd.edu/cancer

More articles from Life Sciences:

nachricht Rainbow colors reveal cell history: Uncovering β-cell heterogeneity
22.09.2017 | DFG-Forschungszentrum für Regenerative Therapien TU Dresden

nachricht The pyrenoid is a carbon-fixing liquid droplet
22.09.2017 | Max-Planck-Institut für Biochemie

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The pyrenoid is a carbon-fixing liquid droplet

Plants and algae use the enzyme Rubisco to fix carbon dioxide, removing it from the atmosphere and converting it into biomass. Algae have figured out a way to increase the efficiency of carbon fixation. They gather most of their Rubisco into a ball-shaped microcompartment called the pyrenoid, which they flood with a high local concentration of carbon dioxide. A team of scientists at Princeton University, the Carnegie Institution for Science, Stanford University and the Max Plank Institute of Biochemistry have unravelled the mysteries of how the pyrenoid is assembled. These insights can help to engineer crops that remove more carbon dioxide from the atmosphere while producing more food.

A warming planet

Im Focus: Highly precise wiring in the Cerebral Cortex

Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.

The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Rainbow colors reveal cell history: Uncovering β-cell heterogeneity

22.09.2017 | Life Sciences

Penn first in world to treat patient with new radiation technology

22.09.2017 | Medical Engineering

Calculating quietness

22.09.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>